ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer's Disease Therapy
작성자: [신한 리서치본부] 제약/바이오() 2025-12-16 07:48
[복사] * 종목을 클릭하면, 종목에 대한 정보를 네이버에서 살펴볼 수 있습니다.
[복사] * 종목을 클릭하면, 종목에 대한 정보를 네이버에서 살펴볼 수 있습니다.
ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer's Disease Therapy
Since 2020, ADEL has been co-developing the asset through a joint research and development agreement with Oscotec Inc.(오스코텍)
https://www.prnewswire.com/news-releases/adel-signs-1-04-billion-global-license-agreement-with-sanofi-for-adel-y01--a-novel-investigational-alzheimers-disease-therapy-302642662.html
/PRNewswire/ -- ADEL, Inc., a biopharmaceutical company dedicated to developing therapies for neurodegenerative diseases such as Alzheimer's Disease, today...
https://mma.prnewswire.com/media/2846061/Logo.jpg?p=facebook
Since 2020, ADEL has been co-developing the asset through a joint research and development agreement with Oscotec Inc.(오스코텍)
https://www.prnewswire.com/news-releases/adel-signs-1-04-billion-global-license-agreement-with-sanofi-for-adel-y01--a-novel-investigational-alzheimers-disease-therapy-302642662.html
/PRNewswire/ -- ADEL, Inc., a biopharmaceutical company dedicated to developing therapies for neurodegenerative diseases such as Alzheimer's Disease, today...
https://mma.prnewswire.com/media/2846061/Logo.jpg?p=facebook
[출처]
PC 프로그램(유료)
PC 프로그램(무료)
안드로이드 앱
